Barzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study--all primary and secondary endpoints met with ...

For some analysts, beyond statistics and graphs of income and travelers. Tourism is measured by the beauty of the landscape, ...

Miv-cel was reported to be well tolerated in the KYSA-8 trial. No high-grade cases of cytokine release syndrome or immune ...

Delayed economic releases guided cautious trading across United States markets, with uneven sector movement and focus on a ...

This study reports a valuable method to predict the capacity of a candidate probiotic bacterium to metabolically outcompete a bacterial pathogen in the ecological niche of the murine respiratory tract ...